“Electrocardiographic and biochemical adverse effects of meglumine antimoniate (MA) during treatment of Syrian cutaneous leishmaniasis patients”, J Pak Assoc Dermatol, vol. 23, no. 4, pp. 412–417, Dec. 2016, doi: 10.66344/jpad.v23i4.289.